Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:CCR5 Δ32 and CTLA-4 +49 A/G gene polymorphisms and interferon-β treatment response in Croatian and Slovenian multiple sclerosis patients
Authors:ID Nekić, Jasna (Author)
ID Stanković Matić, Ivana (Author)
ID Rački, Valentino (Author)
ID Janko Labinac, Dolores (Author)
ID Vuletić, Vladimira (Author)
ID Kapović, Miljenko (Author)
ID Ristić, Smiljana (Author)
ID Peterlin, Borut (Author)
ID Starčević-Čizmarević, Nada (Author)
Files:.pdf PDF - Presentation file, download (271,56 KB)
MD5: 6EEF687C14AC351D146B8D5DCBEC461A
 
URL URL - Source URL, visit https://doi.org/10.3390/ijms25137412
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:The aim of the present study was to investigate the impact of CCR5 Δ32 and CTLA-4 polymorphisms on the response to IFN-β treatment in our cohort of MS patients from Croatia and Slovenia. Genomic DNA was obtained from 295 MS patients (230 female; 65 male) classified as responders (n = 173) and non-responders (n = 122) based on clinical criteria for treatment efficacy. Genotyping was performed via PCR/PCR-RFLP. No significant differences in the genotype/allele frequencies of CCR5Δ32 and CTLA-4 +49 A/G were detected between male responders and nonresponders. A significantly higher prevalence (p = 0.039) of the CTLA-4 +49 AA genotype was found in female responders (42.1%) compared to non-responders (28.9%). Using multiple forward regression analysis, the CTLA-4 +49 AA genotype significantly predicted a positive response to IFN-β therapy in females (p = 0.011) and contributed to 4.5% of response variability. Furthermore, the combined presence of the CCR5Δ32 wtwt/CTLA-4 +49 AA genotype significantly predicted a positive response to treatment in females (p = 0.025). The age at disease onset, pretreatment relapse rate, and baseline EDSS score were not reliable predictors of treatment response in MS patients. Our results indicate that the presence of the CCR5Δ32 polymorphism was not associated with the response to IFN-β treatment, whereas the CTLA-4 +49 polymorphism showed a positive correlation with an optimal response in female patients.
Keywords:multiple sclerosis, polymorphism, treatment response, interferon-β
Publication status:Published
Publication version:Version of Record
Year of publishing:2024
Number of pages:str. 1-11
Numbering:Vol. 25, iss. 13, [article no.] 7412
PID:20.500.12556/DiRROS-28094 New window
UDC:616.8
ISSN on article:1422-0067
DOI:10.3390/ijms25137412 New window
COBISS.SI-ID:239992835 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 19. 6. 2025;
Publication date in DiRROS:10.03.2026
Views:37
Downloads:19
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:International journal of molecular sciences
Shortened title:Int. j. mol. sci.
Publisher:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 New window

Document is financed by a project

Funder:Other - Other funder or multiple funders
Funding programme:University of Rijeka
Project number:uniri-biomed-18-137
Name:Farmakogenetika multiple skleroze: odgovor na imunomodulacijsku terapiju

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Back